ClinicalTrials.gg
CompletedNCT06857253Updated Sep 30, 2026

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1301 in Healthy Subjects

A Phase 1 interventional study of HRS-1301 and HRS-1301 placebo in Hyperlipidemia, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Updated Sep 30, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 1 of them phase 3. Hyperlipidemias · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
7th of 14
84 · median 78
Started
2025
with 4 others
Phase 1
8 of 14
none open now
Registered
7th of 14
by date

Among the 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd., this one is the 7th largest by enrollment, is one of 5 that started in 2025, is one of 8 in phase 1, and was the 7th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

3 of the 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1301 following single and multiple dose administration in healthy subjects. The study consists of two parts (Part 1 and Part 2) with 82 subjects planned to be enrolled. Possible adjustments to sample size, treatment duration and follow-up time will depend upon emerging data.

03

Conditions studied

  • Hyperlipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects must be at least 18 years old and no more than 55 years old on the date of signing the ICF.
  2. The female subjects must be non-pregnant or non-.
  3. Subjects must understand the study procedures and methods, voluntarily participate in this study and sign the ICF in person.

Exclusion criteria

Exclusion Criteria:

  1. Have a gastrointestinal, liver or kidney disease or other condition known to affect drug absorption, distribution, metabolism and excretion or to reduce adherence, as determined by the investigator.
  2. Those who had severe trauma or had undergone surgery within 3 months prior to screening, or planned to undergo surgery during the trial.
  3. Have a history of repeated drug allergies.
  4. People who have used any drug in the 2 weeks prior to screening.
  5. Those who received live (attenuated) vaccine within 4 weeks prior to screening or planned to receive it during the trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    HRS-1301 group

    Drug: HRS-1301

  • Placebo comparator
    HRS-1301 placebo group

    Drug: HRS-1301 placebo

Interventions

  • HRS-1301.

  • DrugHRS-1301 placebo

    HRS-1301 placebo.

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    Time frame: From the first dose up to Day 21.

Secondary outcomes

  1. HRS-1301 plasma drug concentration.

    Time frame: Up to 168 hours after the first dosing.

  2. HRS-1301 urine drug concentration.

    Time frame: Up to 168 hours after the first dosing.

07

Study locations

1 site
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510080, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Aug 2025, 4 months.

Of 47 industry-sponsored phase 1 interventional studies under Hyperlipidemias, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 4 months is above that.

Counting every sponsor, half of 54 studies reached it within 3 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 4, 2025
StartActual
Mar 18, 2025
Primary completionActual
Aug 12, 2025
CompletionActual
Aug 12, 2025
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 11, 2025→Aug 12, 2025
Sep 30, 2026
Study completion
Aug 11, 2025→Aug 12, 2025
Sep 30, 2026
Enrollment
82→84
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Primary completion Aug 11, 2025→Aug 12, 2025
    Study completion Aug 11, 2025→Aug 12, 2025
    Enrollment 82→84
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06857253
Responsible party
Sponsor
First posted
Mar 4, 2025
Start date
Mar 18, 2025
Primary completion
Aug 12, 2025
Completion
Aug 12, 2025
Last update
Sep 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-1301

Start the discussion